Jasper Therapeutics Inc. (JSPR)

$0.46 -0.01 (-1.80%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	12.81M
Revenue (ttm)	0.00
Net Income (ttm)	-75.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	237,500
Avg Vol	533,296
Day's Range	N/A - N/A
Shares Out	28.00M
Stochastic %K	17%
Beta	3.00
Analysts	Sell
Price Target	$7.50

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chroni...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

Zackpedia Jun. 9 at 11:46 PM

$JSPR Down to .42 today, you could’ve sold as I alerted

0 · Reply

Assel17 Jun. 8 at 8:06 AM

$JSPR There is no major positive news at the moment. The stock is still in a "waiting for the big news" phase, and any announcement of: An acquisition offer, A merger, A partnership with a major pharmaceutical company, Or a drug licensing agreement, could have a significant impact on the share price.

1 · Reply